Drugs / MesenCure
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04716998 | Jan 2021 → Jan 2022 | COVID-19 | BonusBio Group Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05497401 | Apr 2026 → Jun 2028 expected | acute respiratory distress syndrome | BonusBio Group Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-20 | BonusBio Group Ltd | Regulatory Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress bonus-bio.com ↗ |
All press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MesenCure | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05497401 ↗ |
| Modality | Cell therapy | “an allogeneic cell therapy product” NCT04716998 ↗ |
| Route | Intravenous | “The IV administration of MesenCure” NCT04716998 ↗ |